Evidence map›Paper›PMID 36359887›Full record

ArticleCells2022

Insights into the Genetic Profile of Two Siblings Affected by Unverricht-Lundborg Disease Using Patient-Derived hiPSCs.

Valeria Lucchino, Luana Scaramuzzino, Stefania Scalise, Michela Lo Conte, Clara Zannino, Giorgia Lucia Benedetto, Umberto Aguglia, Edoardo Ferlazzo, Giovanni Cuda, Elvira Immacolata Parrotta

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valeria LucchinoDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0002-7350-3835
Luana ScaramuzzinoDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0003-3239-3745
Stefania ScaliseDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0001-6979-1486
Michela Lo ConteDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0002-2717-4284
Clara ZanninoDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0003-1919-3212
Giorgia Lucia BenedettoDepartment of Medical and Surgical Sciences, University Magna Graecia, 88100 Catanzaro, Italy.
Umberto AgugliaDepartment of Medical and Surgical Sciences, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0002-4574-2951
Edoardo FerlazzoDepartment of Medical and Surgical Sciences, University Magna Graecia, 88100 Catanzaro, Italy.
Giovanni CudaDepartment of Experimental and Clinical Medicine, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0001-6313-1866
Elvira Immacolata ParrottaDepartment of Medical and Surgical Sciences, University Magna Graecia, 88100 Catanzaro, Italy.ORCID 0000-0001-8145-3623
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unverricht-Lundborg disease (ULD), also known as progressive myoclonic epilepsy 1 (EPM1), is a rare autosomal recessive neurodegenerative disorder characterized by a complex symptomatology that includes action- and stimulus-sensitive myoclonus and tonic-clonic seizures. The main cause of the onset and development of ULD is a repeat expansion of a dodecamer sequence localized in the promoter region of the gene encoding cystatin B (CSTB), an inhibitor of lysosomal proteases. Although this is the predominant mutation found in most patients, the physio-pathological mechanisms underlying the disease complexity remain largely unknown. In this work, we used patient-specific iPSCs and their neuronal derivatives to gain insight into the molecular and genetic machinery responsible for the disease in two Italian siblings affected by different phenotypes of ULD. Specifically, fragment length analysis on amplified CSTB promoters found homozygous status for dodecamer expansion in both patients and showed that the number of dodecamer repeats is the same in both. Furthermore, the luciferase reporter assay showed that the CSTB promoter activity was similarly reduced in both lines compared to the control. This information allowed us to draw important conclusions: (1) the phenotypic differences of the patients do not seem to be strictly dependent on the genetic mutation around the CSTB gene, and (2) that some other molecular mechanisms, not yet clearly identified, might be taken into account. In line with the inhibitory role of cystatin B on cathepsins, molecular investigations performed on iPSCs-derived neurons showed an increased expression of lysosomal cathepsins (B, D, and L) and a reduced expression of CSTB protein. Intriguingly, the increase in cathepsin expression does not appear to be correlated with the residual amount of CSTB, suggesting that other mechanisms, in addition to the regulation of cathepsins, could be involved in the pathological complexity of the disease.

Indexed as

Unverricht-Lundborg SyndromeCathepsinsCystatin BGenetic ProfileHumansSiblingsCathepsinsCystatin Bcystatin Bdisease modelEPM1human induced pluripotent stem cellsiPSCs-derived neuronsUnverricht-Lundborg disease

Identifiers

PMID36359887
PMCPMC9655992
OpenAlexW4308334199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.